Última actualización 6 de julio de 2026
Key finding
The dapagliflozin group showed significant decreases in BMI.
This study compared the effects of dapagliflozin and vitamin E in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, finding significant improvements in several metabolic parameters with dapagliflozin.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study compared the effects of dapagliflozin and vitamin E in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, finding significant improvements in several metabolic parameters with dapagliflozin.
This study highlights the potential of dapagliflozin as a more effective treatment option for patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, which could lead to better management of these conditions and improved patient outcomes.
Intergroup differences in liver enzyme reductions were not significant. No changes were observed in type IV collagen levels. The study may have limited generalizability due to specific population characteristics.
Published in
Publication details and source links for this paper.
Hiroo F, Kazuyoshi K, Reiko Y, et al. Dapagliflozin versus Vitamin E in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes: A Randomized Controlled Trial. Frontiers in Medicine. 2025;12:1542741. doi:10.3389/fmed.2025.1542741
Dapagliflozin group showed significant decreases in BMI.
Dapagliflozin group showed significant decreases in HbA1c.
Dapagliflozin group showed significant decreases in LDL cholesterol.
Both groups demonstrated significant reductions in serum AST and ALT levels.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin and AST, Alanine Aminotransferase (ALT), BMI, and 8 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
11
Evidence pairs
312
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Dapagliflozin → Alanine Aminotransferase (ALT)
Dapagliflozin → Alanine Aminotransferase (ALT)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Adipokine and Angiogenic Markers.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
5 results
2 results
5 results
5 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 80.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
SGLT2 Inhibitors may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Moderate | EvidenceScore™ 63.1 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
SGLT2 Inhibitors appears to improve Body Composition.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.